Related Experiment Video
Updated: Jul 3, 2026

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
Published on: January 7, 2019
[Pharmacological treatment options for prevention of alcohol relapse]
A Heberlein1, S Bleich, J Kornhuber
1Psychiatrische und Psychotherapeutische Klinik, Universitätsklinikum Erlangen, Schwabachanlage 6, Erlangen. annemarie.heberlein@uk-erlangen.de
Abstract:
Many studies address the neurobiological mechanisms of alcohol craving. The study results obtained so far show that there may be at least three subtypes of craving, which may be linked to changes in different neurotransmitter systems. Actually in Germany acamprosate and disulfiram are approved for clinical use for the prevention of alcohol relapse. Also off-label therapy with naltrexone is possible. However studies show that these substances are not effective in all patients. In the light of hypothetical changes in different neurotransmitter systems, subtype specific therapy may be necessary for successful prevention of alcohol relapse. Therefore new therapy options are needed in order to treat alcohol dependent persons. Substances that seem to have efficacy in preclinical or preliminary clinical studies are baclofen, topiramate, odansetron, rimonabant and memantine.
Insights
Understanding alcohol craving subtypes is key to effective relapse prevention. New therapies targeting specific neurotransmitter systems may improve treatment outcomes for alcohol dependence.
Area of Science:
- Neurobiology
- Neuropharmacology
- Addiction Medicine
Context:
- Alcohol craving is a complex phenomenon with potential neurobiological underpinnings.
- Current relapse prevention strategies (acamprosate, disulfiram, naltrexone) show variable efficacy.
- Identifying distinct alcohol craving subtypes may be crucial for personalized treatment.
Purpose:
- To explore the neurobiological basis of alcohol craving.
- To review existing and potential therapeutic interventions for alcohol relapse prevention.
- To highlight the need for subtype-specific treatments.
Summary:
- Neurobiological research suggests at least three subtypes of alcohol craving, linked to different neurotransmitter systems.
- Approved and off-label medications for alcohol relapse prevention are not universally effective.
- Emerging substances like baclofen, topiramate, and others show promise in preclinical or early clinical studies.
Impact:
- Advances in understanding alcohol craving subtypes could lead to more personalized and effective relapse prevention strategies.
- Development of novel pharmacotherapies targeting specific neurotransmitter systems is needed.
- Improved treatment options can enhance recovery outcomes for individuals with alcohol dependence.
More Related Videos
Related Concept Videos
CNS Depressants: Alcohol and Nicotine
Depressants
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Psychosis: Goals of Pharmacotherapy
Drug Abuse and Addiction: Pharmacological Phenomena
Pharmaceutical Poisoning: Treatment Strategies
Protection of Alcohols
Protection
It defines a protecting group as the masking agent to make the more reactive species inert to a given set of conditions. This concept is depicted via the illustration of liquid flow through different outlets in an assembly of pipes. The analogy helps to understand the role...

